For the quarter ending 2026-03-31, XLO made $12,648K in revenue. -$9,529K in net income. Net profit margin of -75.34%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 12,648 | 13,686 | 19,066 | 8,084 |
| Research and development | 19,832 | 18,122 | 14,321 | 15,330 |
| General and administrative | 6,928 | 7,400 | 6,674 | 7,120 |
| Total operating expenses | 26,760 | 25,522 | 20,995 | 22,450 |
| Loss from operations | -14,112 | -11,836 | -1,929 | -14,366 |
| Change in fair value of common stock warrant liabilities | -3,300 | -21,275 | 15,380 | 50 |
| Other income, net | 1,283 | 921 | 1,022 | -1,428 |
| Total other income, net | 4,583 | 22,196 | -14,358 | -1,478 |
| Net gain and comprehensive gain | -9,529 | 10,360 | -16,287 | -15,844 |
| Basic EPS | -0.58 | 1.239 | -0.11 | -0.16 |
| Diluted EPS | -0.58 | -1.048* | -0.11 | -0.16 |
| Basic Average Shares | 16,347,538 | 8,359,109* | 144,106,869 | 96,447,672 |
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)